Navigation Links
Einstein researchers discover 2 new ways to kill TB

March 21, 2010 ─ (BRONX, NY) ─ Researchers at Albert Einstein College of Medicine of Yeshiva University have found two novel ways of killing the bacteria that cause tuberculosis (TB), a disease responsible for an estimated two million deaths each year. The findings, published in the March 21 online issue of Nature Chemical Biology, could lead to a potent TB therapy that would also prevent resistant TB strains from developing.

"This approach is totally different from the way any other anti-TB drug works," says William R. Jacobs, Jr., Ph.D., the study's senior author and professor of microbiology & immunology and of genetics at Einstein, as well as a Howard Hughes Medical Institute investigator. "In the past few years, extremely drug resistant strains of TB have arisen that can't be eliminated by any drugs, so new strategies for attacking TB are urgently needed."

Tuberculosis is caused by the bacterial species Mycobacterium tuberculosis. In searching for a new Achilles' heel for M. tuberculosis, Dr. Jacobs and colleagues focused on an enzyme called GlgE. Previous research had suggested that GlgE might be essential for the growth of TB bacteria. GlgE would also be an excellent drug target because there are no enzymes similar to it in humans or in the bacteria of the human gut.

The GlgE research revealed a previously unknown enzymatic pathway by which TB bacteria convert the sugar trehalose (consisting of two glucose molecules) into longer sugar molecules known as alpha glucans building blocks that are essential for maintaining bacterial structure and for making new microbes through cell division. GlgE was the third of four enzymes involved in this pathway leading to alpha glucans molecules.

Sure enough, when the researchers inhibited GlgE, the bacteria underwent "suicidal self-poisoning": a sugar called maltose 1-phosphate accumulated to toxic levels that damaged bacterial DNA, causing the death of TB bacteria grown in Petri dishes as well as in infected mice.

"We were amazed when we knocked out GlgE that we saw this DNA damage response," says Dr. Jacobs. "That's usually a very effective way to kill bacteria, when you start damaging the DNA."

The researchers discovered a second way of killing TB after observing a crucial connection between their novel alpha glucan pathway and a second pathway that also synthesizes alpha glucans.

When the researchers knocked out one of the other enzymes in their novel pathway, the pathway's shutdown didn't kill the bacteria; similarly, inactivating an enzyme called Rv3032 in the second alpha glucan pathway failed to kill the microbes. But inactivating both of those enzymes caused what the researchers term synthetic lethality: two inactivations that separately were nonlethal but together cause bacterial death.

"The bacteria that cause TB need to synthesize alpha glucans," notes Dr. Jacobs. "And from the bacterial point of view, you can't knock out both of these alpha glucan pathways simultaneously or you're dead. So if we were to make drugs against GlgE and Rv3032, the combination would be extremely potent. And since TB bacteria need both of those alpha glucan pathways to live, it's very unlikely that this combination therapy would leave behind surviving bacteria that could develop into resistant strains."

Dr. Jacobs adds that findings from this study could also enhance treatment of diseases caused by other species of mycobacteria. Leprosy, for example, which still occurs in the U.S. and other countries, is caused by a mycobacterium related to TB. Treating leprosy now involves using several different drugs, some of which are also used to treat tuberculosis.


Contact: Deirdre Branley
Albert Einstein College of Medicine

Related biology news :

1. Einstein researcher receives NIH grant to explore epigenetic regulation of the human genome
2. Einstein researchers receive grants totaling $700,000 for innovative breast cancer research
3. Feinstein researchers develop new genetic method and identify novel genes for schizophrenia
4. In scientific first, Einstein researchers correct decline in organ function associated with old age
5. Einstein researchers develop a new way to study how breast cancer spreads
6. Einstein researchers develop technique to count messages made by single genes
7. Einstein scientists receive $10 million NIH grant
8. Empire State Stem Cell Board awards $12.7 million to Albert Einstein College of Medicine
9. Einstein and Pitt researchers develop new TB test that will dramatically cut diagnosis time
10. NIH funds research center for womens reproductive health at Einstein
11. Einstein researchers devise a fast and sensitive way to detect ricin
Post Your Comments:
(Date:10/26/2015)... PUNE, India , October 26, ... --> --> ... Forecasts 2015 to 2021 as well ... Analysis 2015-2019 research reports to its ... . ...
(Date:10/23/2015)... 2015 Research and Markets ( ) ... Recognition Biometrics Market 2015-2019" report to their offering. ... The global voice recognition biometrics market to grow at ... --> --> The report, Global ... on an in-depth market analysis with inputs from industry ...
(Date:10/22/2015)... SAN JOSE, Calif., Oct. 22, 2015  Synaptics (NASDAQ: SYNA ... results for its first quarter ended September 30, 2015. ... first quarter of fiscal 2016 grew 66 percent over the comparable ... quarter of fiscal 2016 was $23.8 million, or $0.62 per diluted ... net income for the first quarter of fiscal 2016 grew 39 ...
Breaking Biology News(10 mins):
(Date:11/26/2015)... 2015 ... Research Laboratories, a leading independent and ... has formed a strategic partnership with ... Health for joint work on clinical ... ) , --> ,     ...
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE ... has adopted a stockholder rights plan (Rights Plan) in ... operating loss carryforwards (NOLs) under Section 382 of the ... --> PharmAthene,s use of its NOLs could ... change" as defined in Section 382 of the Code. ...
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. ... (Nasdaq: HART ), a biotechnology company developing bioengineered ... Jim McGorry will present at the LD ... 2015 at 2:30 p.m. PT. The presentation will be ... 30 days. Management will also be available at the ...
(Date:11/25/2015)... ... November 25, 2015 , ... A long-standing ... Aerospace Professionals (OPBAP) has been formalized with the signing of a Memorandum of ... with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, ...
Breaking Biology Technology: